Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome
Repetitive transcranial stimulation (rTMS) of the posterior parietal cortex will be applied daily over five days in adult Gilles de la Tourette patients. This approach aims at reducing premonitory sensations believed to induce tics. Patients will be randomized to an active or placebo (sham) group in a crossover design...
Brief Summary
Official Title: “Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome”
Repetitive transcranial stimulation (rTMS) of the posterior parietal cortex will be applied daily over five days in adult Gilles de la Tourette patients. This approach aims at reducing premonitory sensations believed to induce tics. Patients will be randomized to an active or placebo (sham) group in a crossover design.
- Study Type: Interventional
- Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
- Study Primary Completion Date: February 2012
Intervention(s) in this Clinical Trial
- Device: rTMS
- Repetitive transcranial stimulation of the posterior parietal cortex
- Device: Sham rTMS
- Repetitive transcranial stimulation of the posterior parietal cortex
Arms, Groups and Cohorts in this Clinical Trial
- Active Comparator: Stimulation
- Repetitive transcranial stimulation of the posterior parietal cortex
- Sham Comparator: Sham stimulation
Outcome Measures for this Clinical Trial
Primary Measures
- Yale global tic severity scale (YTGSS)
- Time Frame: 3 months
Safety Issue?: Yes
- Time Frame: 3 months
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Gilles de la Tourette syndrome as defined by DSM IV-R
- Yale Global Tics Severity Scale (YGTSS) score between 30 et 60
- Premonitory sensations (" urge to move ")
- Affiliated to the French social security regime
- Ability to give informed consent
Exclusion Criteria:
- rTMS : epilepsy, craniotomy scar, pacemaker or neural stimulator, metal implants or foreign bodies, claustrophobia, pregnancy
- Cognitive impairment (MMS ≤ 24/30)
- Axis I disorders according to DSM IV-R : psychosis or history of psychosis, bipolar illness, major depressive disorder, addictions (except to nicotine)
- Impulse control disorders
- Other chronic debilitating illnesses
- Unability to give informed consent
- Participation in another clinical trial
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 70 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Institut National de la Santé Et de la Recherche Médicale, France Other
Overall Clinical Trial Officials and Contacts
Andreas Hartmann, MD Principal Investigator Institut National de la Santé Et de la Recherche Médicale, France
Overall Contact: Andreas Hartmann, MD +33142161316 andreas.hartmann@psl.aphp.fr
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT01043549
Study ID Number: C08-46
ClinicalTrials.gov Identifier: NCT01043549
Health Authority: France: Afssaps - French Health Products Safety Agency
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01043549
